Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹66.56
1.51 (2.32%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹196 Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
33.0
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹36.3+83.4%
52W High₹164.02-59.4%
Current Price
₹66.56
Circuit Limits (5%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹63.23
Upper Circuit₹69.89
Reference Price
₹66.56
Investment Checklist
Double Top on 1W (BREAKOUT CONFIRMED) — target ₹102.48
Triple Top on 1D (BREAKOUT CONFIRMED) — target ₹130.48
Volume divergence: Bullish (price down, volume up)
EMA(9) Crossover: Price crossed above EMA(9): Fresh bullish momentum signal.
SuperTrend(10,3): Price above SuperTrend (Industry Standard (Swing/Medium-Term))
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
47%
Trend
NEUTRAL
NEUTRAL
Mixed MA signals — sideways/transition
EMA20
62.47
EMA50
60.67
EMA200
86.64
Price Action
MIXED
NEUTRAL
Higher Highs5
Higher Lows3
Lower Highs4
Lower Lows6
Support & Resistance Levels
Resistance (Above)
₹68.11
₹69.93
₹71.90
₹79.70
₹82.44
Support (Below)
₹58.35
₹57.25
₹44.56
₹36.30
Volume Analysis
TrendSTABLE
Change+0.70%
Unusual VolumeNo
Divergence Detected
Bullish (price down, volume up)
Stop Loss Levels
Fixed Risk
1% Risk₹65.89
3% Risk₹64.56
5% Risk₹63.23
7% Risk (Custom)
₹61.90Technical Levels
1x ATR (Volatility)₹62.92
2x ATR (Swing)₹59.28
3x ATR (Trend)₹55.64
Immediate Support₹58.35
Moving Averages
EMA 9 (Short-term)₹65.46
EMA 20 (Medium-term)₹62.47
EMA 50 (Trend)₹60.67
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹22.9 Cr | ₹25.5 Cr | ₹23.5 Cr | ₹16.6 Cr |
| Net Profit | ₹-1.5 Cr | ₹9.6 Cr | ₹8 Cr | ₹5.5 Cr |
| EPS | — | ₹3.25 | ₹2.71 | ₹1.87 |
| Operating Profit | ₹-81,23,000 | ₹10.3 Cr | ₹8.7 Cr | ₹6.1 Cr |
ROE
-10.16%
ROCE
-8.46%
Debt/Equity
0.08
Current Ratio
1.48
OPM
36.54%
NPM
33.19%
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 12 Sept 2024 | Annual General Meeting | AGM |
| 14 Sept 2023 | Annual General Meeting | AGM |
| 28 Jul 2023 | Rights 1:16 @ Premium Rs 65/- | RIGHTS_ISSUE |
| 22 Sept 2022 | Annual General Meeting | AGM |
| 21 Sept 2021 | Annual General Meeting | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for BROOKS
View All
positive
ET Markets - Stocks 32d ago
Unique Picks: 6 stocks held by only one MF scheme in April, falling up to 40% in CY26
An analysis of mutual fund portfolios revealed 29 stocks held exclusively by single schemes, with most underperforming in CY26. However, Satin Creditcare Network, Rossell Techsys, and Amanta Healthcare bucked the trend, delivering strong returns. Brooks Laboratories and EFC (I) were among those experiencing significant declines.
ABSLPSEALPHAALPHAETFAMANTAAONEGOLDAONELIQUIDAONENIFTYAONETOTALAUTOBEESAUTOIETFAXISBNKETFAXISBPSETFAXISCETFAXISGOLDAXISHCETFAXISILVERAXISNIFTYAXISTECETFAXISVALUEAXSENSEXBANK10ADDBANKADDBANKBETFBANKETFBANKPSUBBETF0432BBNPNBETFBBNPPGOLDBFSIBROOKSCHEMICALCHOICEGOLDCOMMOIETFDEFENCEDIVIDENDEBANKNIFTYEBBETF0430EBBETF0431EBBETF0433ECAPINSUREEFCILEGOLDELIQUIDELM250ENERGYENIFTYEQUAL200EQUAL50EQUAL50ADDESENSEXESGESILVERFINIETFFLEXIADDFMCGIETFGILT10BETAGILT5BETAGOLD1GOLD360GOLDADDGOLDBETAGOLDBNDGOLDETFGROWWCAPMGROWWCHEMGROWWDEFNCGROWWEVGROWWGOLDGROWWHOSPIGROWWLIQIDGROWWLOVOLGROWWMC150GROWWMETALGROWWMOM50GROWWN200GROWWNETGROWWNIFTYGROWWNXT50GROWWPOWERGROWWPSEGROWWPSUBKGROWWRAILGROWWRLTYGROWWSC250GROWWSLVRGSEC10IETFGSEC10YEARHCGHCG-REHDFCGOLDHDFCGROWTHHDFCLOWVOLHDFCMID150HDFCMOMENTHDFCNEXT50HDFCNIF100HDFCNIFITHDFCPSUBKHDFCPVTBANHDFCQUALHDFCSILVERHDFCSML250HDFCVALUEHEALTHADDHEALTHCAREHEALTHIETFHSBCGOLDICICIB22INFRAIETFINTERNETITADDITBEESITBETAITETFITIETFLICNETFSENLICNMID100LIQGRWBEESLIQUIDLIQUID1LIQUIDPLUSLIQUIDSBILIQUIDSHRILOWVOLMAFANGMAHKTECHMAKEINDIAMANUFGBEESMASPTOP50METALMETALIETFMID150MIDCAPADDMIDCAPBETAMIDCAPETFMIDCAPIETFMIDQ50ADDMNCMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM30IETFMOM50MOMENTUMMOMENTUM30MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTOURMOVALUEMSCIADDMSCIINDIAMULTICAPNEXT30ADDNEXT50NEXT50ADDNEXT50BETANEXT50ETFNEXT50IETFNIDANNIFTY100EWNIFTYADDNIFTYBETFNIFTYETFNIFTYQLITYOILIETFPHARMABEESPSUBANKADDPSUBNKIETFPVTBANKADDQUALITY30ROSSELLINDROSSTECHSATINSBIBPBSBIETFCONSBIETFITSBIETFPBSBIETFQLTYSBILIQETFSBINEQWETFSBINMID150SBISILVERSELECTIPOSENSEXETFSETF10GILTSILVERSILVER1SILVER360SILVERADDSILVERAGSILVERBEESSILVERBETASILVERBNDSILVERIETFSMALL250SMALLADDSNXT30BEESTATAGOLDTATSILVTECHTNIDETFTOP10ADDTOP20TWCGOLDETFUNIONGOLDVAL30IETFVALUECapital GoodsFast Moving Consumer Goods
neutral
Moneycontrol NaNd ago
Why the Brooks Steriscience–OneSource deal was called off
OneSource Specialty Pharma said its board decided not to proceed 'in its current form' as it was not in the best interest of stakeholders. Brooks Steriscience echoed a similar stance
BROOKSCURRENTONESOURCEConstructionHealthcare